212 related articles for article (PubMed ID: 16134163)
1. GATA1 mutations in myeloproliferative disorders: nomenclature standardization and review of the literature.
Splendore A; Magalhães IQ; Pombo-de-Oliveira MS
Hum Mutat; 2005 Oct; 26(4):390-2. PubMed ID: 16134163
[No Abstract] [Full Text] [Related]
2. [The role of GATA1 mutation in acute megakaryocytic leukemia].
Ito E
Rinsho Ketsueki; 2006 Nov; 47(11):1415-22. PubMed ID: 17176883
[No Abstract] [Full Text] [Related]
3. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
[TBL] [Abstract][Full Text] [Related]
4. Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome.
Heald B; Hilden JM; Zbuk K; Norton A; Vyas P; Theil KS; Eng C
Nat Clin Pract Oncol; 2007 Jul; 4(7):433-8. PubMed ID: 17597708
[TBL] [Abstract][Full Text] [Related]
5. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
[TBL] [Abstract][Full Text] [Related]
6. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
Roy A; Roberts I; Norton A; Vyas P
Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
[TBL] [Abstract][Full Text] [Related]
7. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
[TBL] [Abstract][Full Text] [Related]
8. [GATA1 analysis in myeloproliferative disorders associated to trisomy 21].
Fuster Soler JL; Norton A; Galera Miñarro A; Bermúdez Cortés M; Llinares Riestra ME; Ortuño Giner F
An Pediatr (Barc); 2011 Jan; 74(1):31-7. PubMed ID: 20870473
[TBL] [Abstract][Full Text] [Related]
9. Molecular insights into Down syndrome-associated leukemia.
Vyas P; Crispino JD
Curr Opin Pediatr; 2007 Feb; 19(1):9-14. PubMed ID: 17224656
[TBL] [Abstract][Full Text] [Related]
10. Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome.
Inaba H; Londero M; Maurer SH; Onciu M; Ge Y; Taub JW; Rubnitz JE; Raimondi SC
J Clin Oncol; 2011 Mar; 29(9):e230-3. PubMed ID: 21205752
[No Abstract] [Full Text] [Related]
11. Acute megakaryoblastic leukemia and severe pulmonary fibrosis in a child with Down syndrome: successful treatment with ultra low-dose cytarabine using GATA1 mutation to monitor minimal residual disease.
Moritake H; Yamada A; Kimoto Y; Sawa D; Shimonodan H; Nunoi H
Am J Hematol; 2012 Apr; 87(4):447-50. PubMed ID: 22389016
[No Abstract] [Full Text] [Related]
12. Down syndrome and GATA1-related transient leukemia.
Sandoval C; Pine SR
J Pediatr; 2007 Mar; 150(3):e34. PubMed ID: 17307526
[No Abstract] [Full Text] [Related]
13. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
14. Are GATA1 mutations occurring at random in Down syndrome transient leukemia?
Satgé D
Med Hypotheses; 2014 Aug; 83(2):154-9. PubMed ID: 24880866
[TBL] [Abstract][Full Text] [Related]
15. GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis.
Ariffin H; Garcia JC; Daud SS; Ibrahim K; Aizah N; Ong GB; Chong LA; Mohamad Z
Pediatr Blood Cancer; 2009 Jul; 53(1):108-11. PubMed ID: 19260099
[TBL] [Abstract][Full Text] [Related]
16. Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant.
Shimizu R; Kobayashi E; Engel JD; Yamamoto M
Genes Cells; 2009 Sep; 14(9):1119-31. PubMed ID: 19682090
[TBL] [Abstract][Full Text] [Related]
17. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
Wechsler J; Greene M; McDevitt MA; Anastasi J; Karp JE; Le Beau MM; Crispino JD
Nat Genet; 2002 Sep; 32(1):148-52. PubMed ID: 12172547
[TBL] [Abstract][Full Text] [Related]
18. GATA 1 mutations as clonal markers of minimal residual disease in acute megakaryoblastic leukemia of Down syndrome--a new tool with significant potential applications.
Hitzler J; Zipursky A
Leuk Res; 2005 Nov; 29(11):1239-40. PubMed ID: 15925405
[No Abstract] [Full Text] [Related]
19. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia.
Crispino JD
Pediatr Blood Cancer; 2005 Jan; 44(1):40-4. PubMed ID: 15390312
[TBL] [Abstract][Full Text] [Related]
20. A leukemogenic twist for GATA1.
Look AT
Nat Genet; 2002 Sep; 32(1):83-4. PubMed ID: 12172549
[No Abstract] [Full Text] [Related]
[Next] [New Search]
